Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944104 | 1.00 | PTPN1 (0.43) | PTPN1P2RY14NOTUMHDAC8NPC1 | |
| SCHEMBL4944233 | 0.84 | NOTUM (0.42) | P2RY14NOTUMHDAC8NPC1RAB9A | |
| SCHEMBL4944236 | 0.84 | NOTUM (0.42) | P2RY14NOTUMHDAC8NPC1RAB9A | |
| SCHEMBL4945478 | 0.84 | OXTR (0.57) | HDAC8NPC1RAB9APABPC1POLB | |
| SCHEMBL7132686 | 0.84 | OXTR (0.57) | HDAC8NPC1RAB9APABPC1POLB | |
| SCHEMBL7132689 | 0.84 | OXTR (0.57) | HDAC8NPC1RAB9APABPC1POLB | |
| SCHEMBL4945291 | 0.82 | NOTUM (0.40) | P2RY14NOTUMHDAC8NPC1RAB9A | |
| SCHEMBL4945299 | 0.82 | NOTUM (0.40) | P2RY14NOTUMHDAC8NPC1RAB9A | |
| SCHEMBL4938908 | 0.76 | PABPC1 (0.45) | NOTUMHDAC8NPC1RAB9APABPC1 | |
| SCHEMBL4938914 | 0.76 | PABPC1 (0.45) | NOTUMHDAC8NPC1RAB9APABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-07-10 | — | — | US | disclosed |
| US-7211601-B2 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-05-01 | — | — | US | disclosed |
| EP-1268419-B1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-21 | — | — | EP | disclosed |
| EP-1268418-B1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-14 | — | — | EP | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, PRLHR, NR0B1 | PTPN1 1985/4885P2RY14 1036/4885NOTUM 780/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | PTPN1 1229/4885P2RY14 2792/4885NOTUM 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.